Profile
CDNA DHR-PB TMO DHR A IQV
Company Name CareDx, Inc Danaher Corporation Thermo Fisher Scientific Inc. Danaher Corporation Agilent Technologies, Inc. IQVIA Holdings Inc.
Sector Healthcare Healthcare Healthcare Healthcare Healthcare Healthcare
Industry Medical - Diagnostics & Research Medical - Diagnostics & Research Medical - Diagnostics & Research Medical - Diagnostics & Research Medical - Diagnostics & Research Medical - Diagnostics & Research
Market Cap $977.71M $916.76B $193.40B $146.49B $35.11B $33.79B
Employees 0.64K 79.00K 125.00K 61.00K 18.00K 88.00K
CEO Mr. John Walter Hanna Jr. Mr. Rainer M. Blair Mr. Marc N. Casper Mr. Rainer M. Blair Mr. Padraig McDonnell Mr. Ari Bousbib
Ratings
CDNA DHR-PB TMO DHR A IQV
Quant Rating Score 3 5 3 3 3 3
Quant Rating Neutral Strong Buy Neutral Neutral Neutral Neutral
Trading
CDNA DHR-PB TMO DHR A IQV
Last Close $17.64 $1261.26 $508.9 $204.09 $117.33 $181.43
High 52 $33.99 $1261.26 $624.21 $280.76 $154.64 $254.26
Low 52 $7.56 $1261.26 $508.9 $201.62 $117.33 $181.43
Price vs. 52 Week High -48.1 % 0 % -18.47 % -27.31 % -24.13 % -28.64 %
Price vs. 52 Week Low 133.33 % 0 % 0 % 1.23 % 0 % 0 %
Total Return
CDNA DHR-PB TMO DHR A IQV
1 Month Return -28 % 0 % -4.32 % -1.07 % -12.88 % -6.21 %
3 Month Return -22.83 % 0 % -3.41 % -13.11 % -15.59 % -8.86 %
6 Month Return -38.9 % 0 % -16.73 % -25.58 % -14.55 % -23.99 %
9 Month Return 24.31 % 0 % -11.04 % -19.92 % -9.64 % -14.72 %
YTD Return -17.61 % 0 % -2.18 % -11.09 % -12.66 % -7.67 %
1 Year Return 76.93 % 0 % -13 % -19.4 % -19.2 % -28.64 %
3 Year Return 0 % 0 % 0 % 0 % 0 % 0 %
5 Year Return 0 % 0 % 0 % 0 % 0 % 0 %
Dividends
CDNA DHR-PB TMO DHR A IQV
Dividend Yield Percentage (TTM) - 0.53 % 0.3 % 0.53 % 0.78 % -
Dividend Paid and Capex Coverage Ration (TTM) 25 % 3.1 % 4.37 % 3.1 % 3.01 % 4.51 %
Dividend Per Share (TTM) - 1.08 % 1.56 % 1.08 % 0.96 % -
Payout Ratio (TTM) - 19.7 % 9.2 % 19.7 % 21.92 % -
Growth
CDNA DHR-PB TMO DHR A IQV
Asset Growth 5.19 % -1.42 % -8.22 % 10.06 %
Gross Profit Growth 87.18 % 5.81 % 1.23 % 2.02 %
Revenue Growth 19.07 % 0.05 % -0.06 % -4.73 %
Revenue 3 Year 11.48 % 12.79 % -21.41 % 7.64 %
Revenue 5 Year 109.81 % 75.79 % 29.31 % 36.07 %
Revenue 10 Year 34.71 % 164.64 % 14.22 % 6.72 %
EBIT Growth 120.05 % 6.97 % -6.52 % 10.22 %
Net Income Growth 127.62 % 5.67 % -18.16 % 3.95 %
Net Income 3 Yeari Growth Per Share 269.65 % -15.42 % -41.24 % 11.3 %
Net Income 5 Yeari Growth Per Share 291.06 % 79.48 % 25.73 % 29.88 %
Net Income 10 Yeari Growth Per Share 641.51 % 248.59 % 42.96 % 196.82 %
Operating Income Growth 120.05 % 6.97 % -6.52 % 10.22 %
Operating Cash Flow Growth (CFG) 306.92 % 3.1 % -6.64 % -1.19 %
Operating 3 Year CFG 295.21 % -6.33 % -22.42 % 23.19 %
Operating 5 Year CFG 1197.51 % 82.49 % 64.18 % 85.07 %
Operating 10 Year CFG 225.17 % 244.88 % 69.53 % 181.06 %
EPS Growth 128.25 % 6.76 % -17.86 % 4.98 %
EPS Diluted Growth 126.27 % 7.06 % -17.08 % 5.73 %
Book Value Per Share 47.53 % 7.15 % -7.44 % 1.96 %
Share Holder 3 Year Equity Growth Per Share -19.59 % 25.29 % 6.35 % 14.35 %
Share Holder 5 Year Equity Growth Per Share 205.32 % 74.85 % 58.77 % 34.05 %
Share Holder 10 Year Equity Growth Per Share 0.99 % 151.37 % 101.9 % 27.33 %
Dividend Per Share Growth - 12.64 % -6.53 % 4.47 %
Dividend 3 Year Growth Per Share - 52.23 % 0.35 % 21.3 %
Dividend 5 Year Growth Per Share - 105.55 % 41.45 % 43.54 %
Dividend 10 Year Growth Per Share - 158.83 % 221.34 % 78.17 %
Debt Growth -34.94 % -10.43 % -18.07 % 23.95 %
Free Cash Flow Growth 237.72 % 4.91 % -8.39 % -6.85 %
Updated On 31 Dec 2024 31 Dec 2024 31 Dec 2024 31 Oct 2024
Profitability
CDNA DHR-PB TMO DHR A IQV
Gross Profit Margin TTM 66.78 % 59.5 % 41.49 % 59.5 % 57.75 % 31.44 %
Return on Assets TTM 10.7 % 5.03 % 6.51 % 5.03 % 10.57 % 5.1 %
Return on Equity TTM 17.93 % 7.64 % 13.24 % 7.64 % 20.95 % 21.05 %
Return on Capital Employed TTM 10.17 % 6.87 % 8.73 % 6.87 % 14.73 % 11.27 %
Net Income Per EBT TTM 84.02 % 83.92 % 90.04 % 83.92 % 84.78 % 82.26 %
EBT Per Ebit TTM 153.18 % 95.54 % 95.98 % 95.54 % 100.34 % 74.24 %
EBIT Per Revenue TTM 12.23 % 20.37 % 17.1 % 20.37 % 22.65 % 14.59 %
Cash Flow To Debt Ratio TTM 170.9 % 41.79 % 27.71 % 41.79 % 50.46 % 206.07 %
Receivables Turnover TTM 5.17 6.75 5.23 6.75 4.92 4.06
Payables Turnover TTM 14.43 5.52 - 5.52 5.05 14.35
Inventory Turnover TTM 5.69 4.15 5.04 4.15 2.77 -
Fixed Asset Turnover TTM 576.56 % 478.46 % 460.77 % 478.46 % 359.75 % 1993.27 %
Asset Turnover TTM 67.97 % 30.79 % 44.06 % 30.79 % 54.83 % 57.28 %
Operating Cash Flow Per Share TTM 0.7 9.25 22.69 9.18 5.95 15.18
Free Cash Flow Per Share TTM 0.67 7.33 19.02 7.27 4.94 11.82
Cash Per Share TTM 480.17 % 287.53 % 1458.12 % 285.1 % 514.74 % 1030.18 %
Operating Cash Flow Sales Ratio TTM 11.4 % 28.01 % 20.21 % 28.01 % 25.98 % 17.63 %
Free Cash Flow Operating Cash Flow Ratio TTM 96 % 79.19 % 83.85 % 79.19 % 83.03 % 77.84 %
Cash Flow Coverage Ratios TTM 170.9 % 41.79 % 27.71 % 41.79 % 50.46 % 206.07 %
Price To Free Cash Flows Ratio TTM 26.77 27.54 26.61 27.66 24.92 15.98
Price To Operating Cash Flows Ratio TTM 25.17 22.05 22.6 22.34 20.67 12.62
Price Cash Flow Ratio TTM 25.17 22.05 22.6 22.34 20.67 12.62
Income Statement (TTM)
CDNA DHR-PB TMO DHR A IQV
Revenue $0.33B $23.88B $42.88B $23.88B $6.51B $15.41B
Gross Profit $0.33B $14.21B $18.11B $14.21B $3.54B $5.38B
Gross Profit Ratio 100% 59.5% 42.23% 59.5% 54.3% 34.89%
EBITDA $-0.03B $4.86B $11.54B $4.86B $1.49B $3.45B
Net Income $0.05B $3.9B $6.34B $3.9B $1.29B $1.37B
EPS Diluted 0.93 5.29 16.54 5.29 4.43 7.49
Balance Sheet (MRQ)
CDNA DHR-PB TMO DHR A IQV
Long Term Debt $0.02B $15.5B $29.06B $15.5B $3.35B $0.35B
Total Liabilities $0.11B $27.99B $47.65B $27.99B $5.95B $20.83B
Total Equity $0.38B $49.55B $49.67B $49.55B $5.9B $6.07B
Total Investments $0.15B $0B $1.56B $0B $0.18B $0.11B
Total Debt $0.02B $16.01B $31.28B $16.01B $3.39B $1.32B
Total Assets $0.49B $77.54B $97.32B $77.54B $11.85B $26.9B
Cash Flow Statement (TTM)
CDNA DHR-PB TMO DHR A IQV
Net Income $0.05B $3.9B $6.34B $3.9B $1.29B $1.37B
Inventory $-0B $0.15B $0B $0.15B $0.03B $0B
Dividends Paid $0B $-0.77B $-0.58B $-0.77B $-0.27B $0B
Operating Cash Flow $0.04B $6.69B $8.67B $6.69B $1.75B $2.72B
Capital Expenditure $0B $-1.39B $-1.4B $-1.39B $-0.38B $0B
Related Stocks
Ticker Name Price
A Agilent Technologies, Inc. 121.17
ACRS Aclaris Therapeutics, Inc. 1.555
ADVB Advanced Biomed Inc. Common Stock 3.74
AKU Akumin Inc. 0.2887
APDN Applied DNA Sciences, Inc. 2.225
AWH Aspira Women's Health Inc. 0.1399
BDSX Biodesix, Inc. 0.7279
BIAF bioAffinity Technologies, Inc. 0.367
BIAFW bioAffinity Technologies, Inc. 0.3148
BIOC Biocept, Inc. 0.4349
BNGO Bionano Genomics, Inc. 3.475
BNR Burning Rock Biotech Limited 5.96
CEMI Chembio Diagnostics, Inc. 0.455
CHEK Check-Cap Ltd. 0.7709
CNTG Centogene N.V. 0.325
CO Global Cord Blood Corporation 2.9876
CRL Charles River Laboratories International, Inc. 171.11
CSTL Castle Biosciences, Inc. 19.29
DGX Quest Diagnostics Incorporated 170.17
DHR Danaher Corporation 210.75
ETFs With Exposure to CDNA
Unlock